@Article{Wache2008,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="12",
number="4",
year="2008",
title="Rituximab in haematology and oncology in 10 years of experience",
abstract="Rituximab, a chimeric anti-CD20 monoclonal antibody, used as a single agent or in combination with chemotherapy, has resulted in significant responses in patients with almost every subtype of B-cell lymphoma. Its modulation effects on the immune system have prompted its use in non-neoplastic diseases. Here, based on 10 years of experience, we summarize label and off-label use of rituximab in oncology and haematology. Rituximab mechanisms of action and resistance are discussed.",
author="Wache, Anna
and Gil, Lidia
and Komarnicki, Mieczysław",
pages="173--178",
url="https://www.termedia.pl/Rituximab-in-haematology-and-oncology-in-10-years-of-experience,3,10807,1,1.html"
}